SPONSOR
Mirum Pharmaceuticals, Inc.
Total Trials
4
Recruiting
4
Phases
Phase 3, Phase 2, Phase 2, Phase 3
NCT07200908 Phase 3
Recruiting
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Chronic Hepatitis D Infection
NCT07298330 Phase 3
Recruiting
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Chronic Hepatitis D Infection
NCT05050136 Phase 2
Recruiting
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Primary Biliary Cholangitis
NCT07454837 Phase 2, Phase 3
Recruiting
Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Chronic Hepatitis D